Cancer vaccines represent a novel approach in cancer treatment, leveraging the body’s immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially preventing cancer recurrence and impeding tumor progression. Recent strides in personalized medicine have facilitated the development of tailored cancer vaccines, which target individual tumor characteristics, thereby enhancing efficacy while minimizing adverse effects. Despite some setbacks in the past, ongoing research in immunotherapy, including cancer vaccines, remains a focal point of interest at this year’s AACR conference.

Company

Drug

Indication

Trial Acronym

Phase

Abstract 

Abstract Title

PDC*line Pharma

PDC*lung01

NSCLC

NCT03970746

I/II

CT021

Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC

Elicio Therapeutics

ELI-002 2P

Pancreatic cancer

AMPLIFY-201 (NCT04853017)

I

CT022

Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study

Oncovir

Neoadjuvant Hiltonol (PolyICLC)

Prostate

Cancer

NCT03262103

I

CT023

Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot.

Scancell

SCIB1

Advanced unresectable melanoma

SCOPE

(NCT04079166)

II

CT024

A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial

BioSante

GVAX

Pancreatic adenocarcinoma

NCT03153410

Early Phase I

CT134

Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma

Genentech

Autogene cevumeran (RO7198457, RG6180)

Pancreatic ductal

adenocarcinoma (PDAC)

NCT05968326

II

CT025

Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

Syncromune

SV-102

Metastatic castrate-resistant prostate cancer (mCRPC)

NCT05544227

I

CT026

Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)

For more information on Cancer Vaccines market, refer to DelveInsight’s report:  Cancer Vaccines – Market Insight, Epidemiology and Market Forecast – 2032